Loading
A phase 2/3 trial of Serplulimab, Bevacizumab in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) is a phase 2/3 interventional study registered as NCT04547166 by Shanghai Henlius Biotech, with 568 participants planned, started 2021-03-10 and due to reach its primary completion in 2025-09-24. Interventions recorded: HLX10, HLX04、. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.